

# Jennifer T Loud

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3377020/publications.pdf>

Version: 2024-02-01

40  
papers

2,375  
citations

331670

21  
h-index

289244

40  
g-index

41  
all docs

41  
docs citations

41  
times ranked

4755  
citing authors

#	ARTICLE	IF	CITATIONS
1	Uptake and timing of bilateral and contralateral risk-reducing mastectomy in women with Li-Fraumeni syndrome. <i>Breast Cancer Research and Treatment</i> , 2022, 191, 159-167.	2.5	5
2	Polygenic risk modeling for prediction of epithelial ovarian cancer risk. <i>European Journal of Human Genetics</i> , 2022, 30, 349-362.	2.8	23
3	The predictive ability of the 313 variant-based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant. <i>Genetics in Medicine</i> , 2021, 23, 1726-1737.	2.4	16
4	Identification of 22 susceptibility loci associated with testicular germ cell tumors. <i>Nature Communications</i> , 2021, 12, 4487.	12.8	27
5	Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness. <i>Cancer Research</i> , 2020, 80, 624-638.	0.9	39
6	Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. <i>Nature Genetics</i> , 2020, 52, 56-73.	21.4	120
7	Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants. <i>Genetics in Medicine</i> , 2020, 22, 1653-1666.	2.4	82
8	Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. <i>Nature Genetics</i> , 2020, 52, 572-581.	21.4	265
9	Characterization of the Cancer Spectrum in Men With Germline BRCA1 and BRCA2 Pathogenic Variants. <i>JAMA Oncology</i> , 2020, 6, 1218.	7.1	48
10	Transcriptome-wide association study of breast cancer risk by estrogen receptor status. <i>Genetic Epidemiology</i> , 2020, 44, 442-468.	1.3	32
11	Couples coping with screening burden and diagnostic uncertainty in Li-Fraumeni syndrome: Connection versus independence. <i>Journal of Psychosocial Oncology</i> , 2019, 37, 178-193.	1.2	21
12	Association of Inherited Pathogenic Variants in Checkpoint Kinase 2 (CHEK2) With Susceptibility to Testicular Germ Cell Tumors. <i>JAMA Oncology</i> , 2019, 5, 514.	7.1	43
13	Reproductive factors associated with breast cancer risk in Li-Fraumeni syndrome. <i>European Journal of Cancer</i> , 2019, 116, 199-206.	2.8	10
14	Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers. <i>British Journal of Cancer</i> , 2019, 121, 180-192.	6.4	19
15	Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer. <i>Nature Communications</i> , 2019, 10, 1741.	12.8	90
16	Concordance with BRCA1/2 testing guidelines among women in The Health of Women (HOW) Study. <i>Breast Cancer Research and Treatment</i> , 2019, 173, 719-726.	2.5	5
17	Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study. <i>Journal of the National Cancer Institute</i> , 2019, 111, 350-364.	6.3	30
18	Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. <i>Human Mutation</i> , 2018, 39, 593-620.	2.5	224

#	ARTICLE	IF	CITATIONS
19	Prevalence of pathogenic/likely pathogenic variants in the 24 cancer genes of the ACMG Secondary Findings v2.0 list in a large cancer cohort and ethnicity-matched controls. <i>Genome Medicine</i> , 2018, 10, 99.	8.2	15
20	Mosaic chromosome Y loss and testicular germ cell tumor risk. <i>Journal of Human Genetics</i> , 2017, 62, 637-640.	2.3	34
21	Introduction. <i>Seminars in Oncology Nursing</i> , 2017, 33, 119-120.	1.5	0
22	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. <i>Nature Genetics</i> , 2017, 49, 1767-1778.	21.4	289
23	Prevalence of Cancer at Baseline Screening in the National Cancer Institute Li-Fraumeni Syndrome Cohort. <i>JAMA Oncology</i> , 2017, 3, 1640.	7.1	43
24	Baseline Surveillance in Li-Fraumeni Syndrome Using Whole-Body Magnetic Resonance Imaging. <i>JAMA Oncology</i> , 2017, 3, 1634.	7.1	148
25	Research participant interest in primary, secondary, and incidental genomic findings. <i>Genetics in Medicine</i> , 2016, 18, 1218-1225.	2.4	24
26	Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li-Fraumeni syndrome cohort. <i>Cancer</i> , 2016, 122, 3673-3681.	4.1	346
27	Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. <i>Nature Communications</i> , 2016, 7, 12675.	12.8	78
28	Nontesticular cancers in relatives of testicular germ cell tumor (TGCT) patients from multiple TGCT families. <i>Cancer Medicine</i> , 2015, 4, 1069-1078.	2.8	2
29	Rare inactivating PDE11A variants associated with testicular germ cell tumors. <i>Endocrine-Related Cancer</i> , 2015, 22, 909-917.	3.1	24
30	Prospectively Identified Incident Testicular Cancer Risk in a Familial Testicular Cancer Cohort. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 1614-1621.	2.5	4
31	Germline Mutation in BRCA1 or BRCA2 and Ten-Year Survival for Women Diagnosed with Epithelial Ovarian Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 652-657.	7.0	138
32	Effects of false-positive cancer screenings and cancer worry on risk-reducing surgery among BRCA1/2 carriers. <i>Health Psychology</i> , 2015, 34, 709-717.	1.6	19
33	Circulating estrogens and estrogens within the breast among postmenopausal BRCA1/2 mutation carriers. <i>Breast Cancer Research and Treatment</i> , 2014, 148, 691-692.	2.5	1
34	Circulating estrogens and estrogens within the breast among postmenopausal BRCA1/2 mutation carriers. <i>Breast Cancer Research and Treatment</i> , 2014, 143, 517-529.	2.5	13
35	Ductal Lavage in Women from BRCA1/2 Families: Is There a Future for Ductal Lavage in Women at Increased Genetic Risk of Breast Cancer?. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 1243-1251.	2.5	25
36	Tolerability of breast ductal lavage in women from families at high genetic risk of breast cancer. <i>BMC Women's Health</i> , 2009, 9, 20.	2.0	12

#	ARTICLE	IF	CITATIONS
37	Disclosure of positive BRCA1/2-mutation status in young couples: The journey from uncertainty to bonding through partner support.. Families, Systems and Health, 2008, 26, 296-316.	0.6	36
38	Deliberate Deceit of Family Members: A Challenge to Providers of Clinical Genetics Services. Journal of Clinical Oncology, 2006, 24, 1643-1646.	1.6	15
39	The art and science of cancer nursing in the genomic era. Seminars in Oncology Nursing, 2004, 20, 143-144.	1.5	2
40	Applications of Advances in Molecular Biology and Genomics to Clinical Cancer Care. Cancer Nursing, 2002, 25, 110-122.	1.5	5